Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Takeda opens recruitment in phase II study of TAK-079 for generalized myasthenia gravis

Jan. 8, 2020

Escape reports phase I data on oral S1P5 receptor agonist ESB-1609

Jan. 8, 2020

New muscarinic M1 receptor antagonists presented by Pipeline Therapeutics

Jan. 3, 2020

Chemrar Research & Development Institute discloses dopamine D2 and D3 receptor agonists

Jan. 3, 2020

Viral infection may be second hit for familial ALS

Jan. 3, 2020

Herantis advances xCDNF program into lead optimization

Jan. 2, 2020

Spot on: Breaching all three meninges improves drug delivery to brain

Jan. 2, 2020

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

Dec. 31, 2019

Wave reports topline data from ongoing phase Ib/IIa study of WVE-120102 for Huntington's disease

Dec. 30, 2019

Phase III MOMENTUM trial of AXS-08 for migraine meets coprimary endpoints

Dec. 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...